Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn’s Disease

Abstract Background There is a need to better understand the positioning of biologic therapies for long-term outcomes in biologic-naïve Crohn’s disease (CD). We assessed the comparative effectiveness of infliximab and ustekinumab among induction responders for 1-year outcomes. Methods This post hoc...

Full description

Saved in:
Bibliographic Details
Published in:Inflammatory bowel diseases 2023-07, Vol.29 (7), p.1015-1023
Main Authors: Wong, Emily C L, Dulai, Parambir S, Marshall, John K, Jairath, Vipul, Reinisch, Walter, Narula, Neeraj
Format: Article
Language:English
Subjects:
Biological Products - therapeutic use
Crohn Disease - chemically induced
Crohn Disease - drug therapy
Humans
Infliximab - therapeutic use
Remission Induction
Treatment Outcome
Ustekinumab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background There is a need to better understand the positioning of biologic therapies for long-term outcomes in biologic-naïve Crohn’s disease (CD). We assessed the comparative effectiveness of infliximab and ustekinumab among induction responders for 1-year outcomes. Methods This post hoc analysis included data from 220 biologic-naïve CD participants with response to induction therapy from 2 clinical trial programs. Participants achieving 1-year clinical remission (CR) (Crohn’s disease activity index
ISSN:1078-0998
1536-4844
DOI:10.1093/ibd/izac168